Ascorbic acid is the single-nutrient supplement most commonly used by cancer patients, although in most cases this takes place without the physician's knowledge or supervision. A comprehensive review of the literature is presented on the impact of ascorbic acid on cancer survival. Findings from 6 uncontrolled studies suggest that ascorbic acid may increase survival, whereas 2 controlled trials have yielded null results. The relative strengths and limitations of these studies are discussed. A turning point occurred with the release of the 2 controlled (null) studies, which influenced many physicians to turn away from nutrition in the care of cancer patients. Controversy about these trials still persists, however, in the alternative cancer community.
In 1980, 2-time Nobel Prize winner Linus Pauling stated in the New England Journal of Medicine: "We are quite confident that, in the not too distant future, supplemental ascorbate will have an established place in all cancer treatment regimes." 1 At that point in time, many oncologists seemed on the verge of embracing the therapeutic efficacy of nutritional factors in cancer care. Dr. Pauling's work throughout the 1970s had generated considerable scientific and public interest in the potential usefulness of ascorbic acid (ascorbate, vitamin C) as an adjunct to cancer therapy. His first study, conducted in Scotland, was also the most famous because it ignited fierce controversy. 2 Prior to this, Pauling had publicly questioned the adequacy of the recommended daily allowance (RDA) for ascorbic acid and recommended gram doses for the prevention and treatment of colds. 3 At that time, the RDA for vitamin C, 45 mg/day, was based solely on estimates of levels needed for prevention of scurvy; these estimates have been as low as 10 mg/day. 4, 5 It is not surprising that the ascorbate-cancer debate continued to intensify when supraphysiologic doses in the range of 5 to 30 grams were proposed to be effective in the treatment and late-stage management of malignant disease. 6 To this day, the very mention of Pauling's research on ascorbic acid sparks heated arguments among nutritionists and oncologists.
Investigations into the potential usefulness of supplemental ascorbate in cancer treatment began in Scotland in 1971. The results of these early studies were strikingly favorable, although weaknesses in design led to their eventual rejection. The findings were intriguing because survival differences between ascorbate-treated and untreated patients were consistently large. Claims of therapeutic efficacy warranted immediate testing in the form of randomized controlled clinical trials (RCCTs). Two such trials were conducted, both by the Mayo Clinic in Rochester, Minnesota, funded by the National Institutes of Health. No effect of high-dose ascorbate was found. However, neither trial followed the ascorbate protocol used in the Scottish studies, and the results have since been regularly questioned in the alternative health community.
Ascorbic acid is one of the micronutrients most likely to be used in quantities substantially in excess of the RDA by the U.S. public. 7 It seems likely that cancer patients are even more likely to take supplemental ascorbate. Vitamin supplementation is among the most popular forms of complementary medicine currently in use by cancer patients. 8 More than 50% of all cancer patients now use vitamin supplements, botanical agents, or some other complementary modality, some without informing or consulting their oncologist. 9, 10 In 1985, it was estimated that 100,000 cancer patients self-prescribed the vitamin based on a popular belief in its medicinal properties. 11 More than 2000 patients were treated with pharmacological doses of ascorbate in studies conducted in Scotland, [12] [13] [14] Japan, 15, 16 and Canada. 17 Proponents have usually viewed ascorbate as a supportive measure administered in tandem with standard cancer therapy, rather than as an alternative to conventional treatment. This article presents an overview of the literature on the impact of ascorbic acid on cancer survival and considers the findings from the 8 clinical studies conducted to date in terms of their strengths and limitations.
Studies Showing a Favorable Impact on Survival
The majority of studies on ascorbate and cancer relate to its preventive potential. Most of these studies concern dietary ascorbic acid, which is a weak measure because of collinearity with other protective food factors such as bioflavonoids, carotenoids, and fiber. A 1992 national survey, for instance, found that agespecific death rates for cancer among individuals with the highest ascorbate intake was 22% lower for men and 14% lower for women than for those with lower intakes. 18 To date, 8 studies have analyzed the potential impact of supplemental ascorbate on the survival of advanced cancer patients. The varying designs and sizes of these studies make direct comparisons difficult and in some cases impossible. Thus, an assessment of the literature demands consideration of each study's strengths and weaknesses and comparisons of the specific interventions and outcomes to ensure relevance to the overall analysis.
The findings obtained from the published reports on cancer patients treated with supplemental ascorbate are summarized in Table 1 . The first study, conducted by Ewan Cameron, MD, and colleagues at the Vale of Leven Hospital in Loch Lomondside, Scotland, was a nonrandomized, uncontrolled trial that began in 1971. 12 Cameron had postulated that highdose ascorbate could improve the treatment of advanced cancer. Fifty patients with various advanced cancers who were considered "terminally ill" were prescribed a daily dose of 10 grams ascorbate. During the observation period (660+ days), 17 patients showed no response, whereas 10 had a minimal response. Six patients experienced hemorrhage and tumor necrosis, which caused complete tumor regression but also resulted in the patients dying. Of the remaining patients, however, 11 had evidence of slowed tumor growth, 3 showed a cessation of tumor growth, and 5 showed an objective tumor regression with long-term survival.
The findings surpassed the life expectancy of these patients. Based on previous data from similar groups of "terminal" patients, it had been expected that 90% of the ascorbate-supplemented group would die within 3 months of being declared untreatable. By the end of the third month, only 25 (50%) of the ascorbate-supplemented patients had died. Of the remaining 25 patients, 20 died between days 110 and 659, with a mean survival of 261 days. The 5 patients who showed objective tumor regression (without hemorrhage or necrosis) had an average survival time of greater than 610 days. 12 In view of these preliminary findings, Cameron and Pauling (1976) began a retrospective evaluation of terminal cases that had been treated with supplemental ascorbic acid at Cameron's hospital in Scotland. 2 The designation of "terminal" was based on a variety of conventional methods such as the establishment of inoperability at laparotomy, admission for palliative nursing care, and the physician's ascertainment that no standard therapy remains. The intervention group was composed of randomly selected patients from the database of all those untreatable cancer patients who had received ascorbate at the Vale of Leven Hospital. Each of these patients (n = 100) was then matched for age, sex, and type and stage of cancer with 10 unsupplemented controls from the same hospital, for a total of 1000 control patients.
The mean survival time in this group of mixed untreatable cancers, all of whom received 10 grams of ascorbate daily, was 210 days as compared with 50 days for the unsupplemented control patients. Thus, survival for the ascorbate intervention was on the average 4.2 times longer than for the historical controls. In 90% of the cases, the ascorbate group lived 3 times longer than the control group. The remaining patients were all still alive at the study's conclusion. At the time of the study's publication (1976), these ascorbate-supplemented patients showed greater than 20 times the survival rate of patients in the control group. 6 Understandably, these impressive numbers ignited an explosion of public interest in the potential efficacy of ascorbic acid as an adjunct to cancer therapy. It was claimed that, as a result, many thousands of patients began self-prescribing the vitamin. 19 Some scientists criticized the study's design on the grounds that it was retrospective (thus more subject to bias) and lacked appropriate controls. Subjects in the intervention and control groups may not have been selected with sufficient rigor from the same representative subpopulations in terms of tumor type and stage. Determinations regarding the point of untreatability or "terminal" status could have also differed between the intervention and control groups.
In response to these criticisms, Cameron and Pauling undertook a second retrospective evaluation utilizing many of the same patients from the first study. 13 Again, 100 patients receiving ascorbic acid were compared with 1000 matched controls without ascorbate. Excluded from the analysis were any patients for whom the records did not permit the date of untreatability to be reliably determined. Most of the ascorbate group (90%) and about half the controls were the same subjects as in the initial study. In the second study, however, the groups were more carefully matched according to types and stages of cancer to control for differences in mean survival times among different cancers. This resulted in replacement of 10 patients in the intervention group who had very rare forms of cancer that precluded precise matching. Applying such methods, the investigators believed they had established a matched control group that was entirely contemporaneous with the ascorbate-treated patients. Various statistical procedures were applied to test the validity of the ascorbate-supplemented patients and their controls as randomly selected subpopulations of the same hospital population of terminal cancer patients. It was also established statistically that no systematic error had been made in the determination of the dates of untreatability, and thus comparable times of untreatability had been assigned to the 2 groups.
In each of the 9 types of cancer, the ascorbate-supplemented group showed a significantly longer survival time than their matched controls. The average survival differential was more than 300 days (P < .01). Indeed, survival of patients taking the vitamin, from the date when each patient's disease became untreatable, actually improved over the results of the previous analysis. Survival times greater than 1 year from the date of untreatability were observed for 22 of the 100 ascorbate-treated patients. These 22 patients had a mean survival of 2.4 years. At the time of evaluation, 8 patients in the ascorbate group were still alive (with a mean survival of 3.5+ years), whereas no one had survived in the control group. Even after factoring out those 8 exceptional survivors, the ascorbate group lived an average of 251 days longer than the control group.
Uncontrolled trials of supplemental ascorbate conducted at 2 separate cancer clinics in Japan during the 1970s also indicated an improvement in survival. A total of 130 terminal cancer patients received either low (less than 4 g/day) or high (averaging 25 g/day) doses of ascorbate. At the Fukuoka Torikai Hospital, the mean survival time after being declared terminal was 43 days for 44 patients treated with low-dose ascorbate (less than 4 g/day) and 246 days for 55 patients treated with high-dose ascorbate (greater than 5 g/day, averaging 25 g/day) from the time of being labeled "terminal." 15 However, there was no difference in survival times between those patients receiving moderately high ascorbate doses (5-9 g/day) and those receiving very high doses (10-29 g/day); intriguingly, a reduction in effectiveness was found among patients treated with extremely high doses (30-60 g/day). It is possible that patients diagnosed with the most aggressive cancers also received the highest doses, which would have biased the results toward the null. The strongest positive impact of ascorbate on cancer survival involved uterine cancer patients, whereas patients with lung or stomach cancers experienced the smallest benefit. The other group of patients, treated at the Kamioka Kozan Hospital, consisted of 6 terminal patients supplemented with high-dose ascorbate (again, averaging 25 g/day) who lived an average of 115 days, compared with 19 unsupplemented (control) patients who showed a mean survival of 48 days. 16 In summary, patients at the Kamioka Kozan and Fukuoka Torikai hospitals in Japan who were treated with high-dose ascorbate survived 2.4 and 5.7 times longer, respectively, than patients on either no ascorbate or low-dose ascorbate, respectively. The very high doses were tolerable because they were administered intravenously, thus bypassing the problem posed by bowel intolerance to megadoses of oral ascorbate. The problem of bowel intolerance can be significant in oral high-dose ascorbate protocols, due to the common development of osmotic diarrhea among patients receiving overdoses exceeding 6-7 grams per day. 20, 21 The Japanese studies may also be interesting because Japanese patients also consume low-fat diets that tend to be high in other anticancer factors such as omega-3 fatty acids as well as soy isoflavones, which might affect survival, in addition to ascorbate.
Cameron and Campbell later (1991) reported on a nonrandomized clinical trial of cancer patients who had reached an untreatable stage upon being admitted to 3 Scottish hospitals. 22 The majority of the breast cancer patients within the study received radiation soon after primary breast surgery; a number of the patients with either lung or bladder tumors also underwent radiotherapy. Excluded from this study were all patients who had taken micronutrient supplements in addition to ascorbate as well as patients who had undergone substantial chemotherapy (at least 3 months on a multidrug regimen). Of the 1828 terminal cases, 294 received high-dose ascorbate; the remaining 1532 cases composed the control group. The ascorbate supplementation protocol consisted of 10 g/day, to be continued indefinitely thereafter. Many patients were initially treated by intravenous ascorbate for 10 days.
The intervention group showed excellent adherence based on plasma and leukocyte ascorbate levels, which were estimated every 4 weeks in virtually every test patient. Only 1 control patient was suspected of self-medicating with ascorbate based on these tests. Instead of using the date of untreatability as the starting point, the researchers elected to measure overall survival time from the date of first hospital attendance to the date of death, or the date of conclusion of the study if the patient was still alive at that point. Ascorbate-supplemented patients showed a median overall survival time almost double that of the controls (343 vs 180 days, P < .0001). For ascorbate-treated patients, a linear relationship was reported between the highest recorded plasma ascorbate concentration and overall survival time, with values of > 3 mg/dl being optimal. Other indicators of decreased malignant activity among ascorbate-treated patients included a decrease in malignant ascites and pleural effusion, relief from hematuria, partial reversal of hepatomegaly and jaundice, and reductions in erythrocyte sedimentation rate and serum seromucoid levels. 6 The investigators concluded that "incurable patients coming under the care of physicians who routinely prescribed supplemental ascorbate lived quite significantly longer than those coming under the care of physicians who did not, at least in the three Scottish hospitals studied." 22 In a retrospective study of advanced cancer patients, Hoffer and Pauling (1993) examined the clinical outcomes among cancer patients who received a mixture of high-dose ascorbate and 8 other micronutrients. Of 134 cancer patients, 101 patients followed a mixed vitamin-mineral regimen that included 12 g ascorbate. These patients had 4 times higher survival than the 31 unsupplemented controls. 17 Of the 101 patients who followed a mixed vitamin regimen that included 12 grams of ascorbic acid, 40% were considered "excellent responders" with a survival time of 5 or more years. However, the control group in this study was too small to make statistical comparisons. It would have been more instructive to compare patients on the mixed supplement regimen with 2 larger control groups, one consisting of patients on high-dose ascorbate alone and the other not supplemented.
The main criticism of these 6 studies is that they were uncontrolled and lacked randomization (or proper randomization procedures), and hence were subject to bias. Most of these studies were retrospective rather than prospective. Because the subjects were not randomly assigned to groups in advance but were selected retrospectively, it is possible that selection bias occurred, with the researchers consciously or subconsciously selecting the ascorbate-treated patients who had more favorable prognoses to be part of the intervention group. However, it is usually the more severely ill patients (ie, the ones with more serious prognoses) who are most willing to try a new treatment, regardless of its potential dangers. 23 Such patients would presumably believe they have less to lose by considering experimental or unorthodox therapies. A more basic problem in the Vale of Leven studies was the heterogeneity of cancers in these studies. Only relatively small numbers of patients with the same type of cancer were included, making it impossible to draw meaningful conclusions about the possible impact of ascorbate on specific types of cancer.
Studies Showing a Null Effect on Survival
In an attempt to test the findings of Cameron and Pauling, 2 prospective, randomized trials of ascorbate supplementation in patients with advanced cancers were conducted, both at the Mayo Clinic. In a trial directed by Creagan et al, subjects (n = 150) were randomized to either 10 grams of ascorbate daily in 4 divided doses or to an equal number of placebo capsules. 24 These groups were considered evenly balanced with regard to age, sex, tumor site, initial performance status, and previous treatment. Twenty-seven patients elected not to participate after randomization and thus became a second control group ("no treatment"), leaving 60 patients in the ascorbate-treated group and 63 in the placebo-treated group. The intervention was implemented until death or until the patient was no longer able to ingest the capsules. All but 9 of the 123 subjects had received prior chemotherapy, radiation, or both, as would be expected for patients with highly advanced metastatic disease.
The survival curves between the ascorbate-treated and placebo-treated groups were essentially identical. Of potential importance was the finding that the 27 no-treatment patients (dropouts) had approximately half the survival rate of either the ascorbate-or placebo-treated patients. This difference may not be clinically valid, however, since the prognostic characteristics of the no-treatment patients may have been less favorable than in the other 2 groups. Another possibility is that some patients in the placebo group were selfmedicating with ascorbate (implying an identifiable placebo), as was documented in the subsequent study by the same investigators. If this occurred, then the more valid control group would have consisted of the no-treatment patients. Unfortunately, the specific attributes of the no-treatment group were never reported, and adherence to the intervention arms was not carefully controlled in the other 2 groups.
Pauling criticized the Creagan study on the grounds that it had not addressed the effect of ascorbate on advanced cancer patients not previously treated with intensive chemotherapy. 1 This was a striking difference between patients treated at the Vale of Leven Hospital and those in the Creagan study: whereas virtually all of the Creagan study patients had undergone chemotherapy, only 4% of the patients in Cameron and Pauling's study had received chemotherapy. A related criticism concerns the condition of the Creagan patients upon entering the study. Average survival was only 51 days for both groups of patients. This low survival rate for the group suggests that the prognoses were extremely poor at baseline and that the cancers were too far advanced or aggressive to reasonably expect any intervention to affect the outcome.
Acknowledging these limitations, the same researchers undertook a second trial, led by Moertel, this time including only patients with advanced colorectal cancer. 19 (This tumor type, the one most commonly treated by Cameron and Pauling, had shown a particular survival advantage from their ascorbate protocol.) All were considered to be "beyond any reasonable hope of potentially curative surgery or radiation therapy," and none had undergone chemotherapy prior to the study's initiation. One hundred patients were randomly assigned to either ascorbate (10 g/day) or placebo (lactose). The treatment was maintained for as long as patients were able to take oral medications or until there was evidence of marked progression of malignant disease. Progression was based on a substantial increase (> 50%) in known areas of malignant disease, indications of disease spread, a substantial decline in performance status, or decreased body weight (10% or more). At the point of progression, more than half of the subjects received subsequent chemotherapy, with the proportion being comparable between treatment arms (57.1% and 58.8%).
None of the patients died during treatment with the high-dose ascorbate. As with the first RCCT, however, the survival curves basically overlapped between the 2 groups. After 1 year, 49% of the ascorbatetreated group and 47% of the placebo-treated group were still alive. Actual survival times could not be fairly determined, however, because participation in the study was discontinued prematurely for about 60% of the patients, who were then given 5-FU chemotherapy. The high-dose ascorbate was halted after a median interval of 2.5 months, and after 3.6 months for the placebo group; this disparity reflected nonsignificant
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Among the main criticisms of the Cameron and Pauling study was that clinicians who prescribed ascorbate at the time may have done so with a subconscious or conscious bias toward patients with more favorable prognostic characteristics. This source of bias would have been minimized by randomization to ascorbate and placebo groups. To emphasize this point, Moertel and colleagues selected only those patients who showed a more favorable prognosis at the outset based on tumor characteristics and performance status. The result was that both groups showed survival similar to the ascorbate-treated groups in the study by Cameron and Pauling, implying that selection bias in the Vale of Leven study may have been at work. There is no way, however, to determine whether patients who received ascorbate in the Vale of Leven study were selected based on favorable prognostic characteristics. This does not seem likely, since the Vale of Leven physicians were unaware that they were participating in a clinical study, and, as noted above, patients who are willing to receive experimental or "unproven" treatment are typically the ones who are faced with more aggressive disease and hence less favorable prognoses. 23
Additional Concerns Raised About the Creagan and Moertel Studies
A number of other criticisms of the randomized studies have since been raised by the alternative community and by researchers in the area of nutritional oncology. Some concern the chemistry and pharmaceutics of the ascorbate preparations employed. Prasad et al suggested that the disparity between the studies may be attributed, in part, to differences in the chemical form of the vitamin (ascorbic acid vs sodium ascorbate, which is more bioavailable). 25 Similarly, the randomized studies utilized a fast-disintegrating ascorbic acid capsule, which has significantly lower bioavailability than capsules designed for slow disintegration. 26 Creagan, Moertel, and colleagues had argued that physicians in the Van Leven studies did not provide objective measures of adherence. The Mayo researchers reported that they monitored their patients carefully and documented ascorbate intake such that "total doses were known to be at least 75 percent of the expected amount in all but eight patients." 19 Urine tests indicated strong adherence but were performed in only 5 patients in the ascorbate group and 6 in the placebo group. 27 Of the 6 placebo patients tested, 5 had levels that the researchers considered to be within the acceptable range for normal controls. One of these controls excreted over 1200 mg ascorbate, and the others nearly 500 mg. However, it has been pointed out that unsupplemented cancer patients normally excrete no more than 10 mg ascorbate per day, and excretion of 500 mg could be an indication that pharmacologic doses are being taken. [28] [29] [30] Although the 500 mg level could indicate deficiencies in laboratory analytical technique as well as selfdosing, even in that case the patient excreting 1200 mg could arguably represent supplementation. Thus, some control patients in the Moertel study may have taken ascorbate on their own, which would tend to diminish survival differentials between groups. This could be explained on the basis that (1) the placebo might have been identifiable (thus technically no longer a placebo), (2) Cameron and Pauling's success with high-dose ascorbate in advanced cancer had been widely publicized, and (3) placebo patients cannot be stopped from self-medicating. Advanced cancer patients who are told they are untreatable could be more likely to self-prescribe a widely available vitamin, particularly one touted as a potent anticancer agent, than knowingly ingest an inactive substance. On the other hand, if the placebo and active medications were identifiable, the ascorbate group could also have realized that they were the experimental group and could have been subject to the classic placebo effect from taking an experimental medication, which might have contributed to a longer survival, although doubts have recently been raised about this possibility. 31 Patients were apparently not surveyed to determine whether they thought they were in the ascorbate or placebo groups.
Another frequent criticism of the Moertel study was that it failed to follow the high-dose ascorbate protocol outlined by Pauling and Cameron. Ten grams per day were reportedly taken in both the null studies and the favorable studies. The Moertel protocol simply involved taking twenty 500 mg capsules of ascorbic acid each day; patients were asked to take 5 capsules 4 times daily. However, the Vale of Leven protocol involved a 10-day course via continuous slow-drip infusion of 10 grams sodium ascorbate in half-strength Ringer's Lactate Solution. 32 After this intravenous treatment, assuming the patient could take oral medication, ascorbic acid was begun orally, in the form of a syrup, at a dose of 2.5 grams every 6 hours for a total dose of 10 g/day. The dosage varied in the range of 10-30 g/day, depending on disease severity, and was continued indefinitely. The objective was to maintain plasma ascorbate levels of at least 3 mg/dl. Intravenous administration reportedly enables patients to develop bowel tolerance to ascorbate, and thus avoid the diarrhea that otherwise accompanies high ascorbate doses. The Mayo Clinic researchers acknowledged that "drug intolerance" (they did not specify diarrhea, the only immediate reaction associated with high-dose ascorbate) was among the primary reasons for the period during which patients stopped taking high-dose ascorbate (14% of the intervention period). 27 A related criticism was that, at a median time of only 2.5 months, the Moertel study halted ascorbate supplementation. This was done after observing signs of disease progression or deteriorating performance status. The latter effect may have been due to malabsorption secondary to osmotic diarrhea, as would have occurred without first establishing bowel tolerance. 33, 34 Discontinuing high-dose ascorbate purportedly results in a "rebound effect" or sudden drop in serum ascorbate that may result in immune suppression and increased oxidative stress to normal tissue. 30, 32, 35, 36 Even aside from the potential ramifications of the rebound effect for the condition of the ascorbate patients, it has been suggested that ascorbate treatment was terminated prematurely in the Moertel trial. As Hennekens and Buring suggested, such findings as tumor enlargement might well be only transient and disappear or even reverse after more data from the group have accumulated. 37 In an interview published in 1998, Pauling offered the observation that the timeframes of the Moertel trial differed dramatically from those adhered to in the Vale of Leven studies. 38 Whereas all the Vale of Leven patients received ascorbate during the entire study period of the trial, the Moertel patients underwent 4 successive periods of different treatment: (1) ascorbate received every day for a median time of 2.5 months; (2) ascorbate treatment halted, based on the clinical investigators' judgment; (3) chemotherapy drugs administered; and (4) no treatment following chemotherapy. Only the first of these 4 periods resembled the Vale of Leven protocol, and yet it lasted only a median of 2.5 months. No one died during that period. After termination of high-dose ascorbate, the ascorbate and placebo patients died off at about the same rate. This is what would be expected, because ascorbic acid is water-soluble and rapidly excreted in the urine, thus precluding the therapeutic benefit after terminating the administration of ascorbate. Thus, in the view of advocates of high-dose ascorbate treatment, and of many in the alternative cancer treatment community, the Vale of Leven protocol has never been satisfactorily studied in the context of a randomized trial. So where do we stand today? More than a quarter-century later, the controversy ignited by Pauling and Cameron continues to smolder, with a largely unsubstantiated disregard by a significant portion of medical oncologists. Meanwhile, numbers of cancer patients continue to take vitamin C to counteract their illness. Despite this, with no studies planned, we are left with no satisfactory resolution on the horizon.
